Top Telehealth Stocks: Our 7 Picks for August 2026 Ranked
Seven telehealth stocks are ranked by investment quality, balancing recurring care models, growth, profitability, valuation, earnings execution, and analyst expectations.
Telehealth has moved beyond its pandemic-era identity as a substitute for an office visit. It now sits at the intersection of consumer demand for convenience, employer and payer efforts to reduce care costs, and provider shortages that make virtual access a practical necessity. For investors, that evolution creates a broader opportunity set: companies can monetize consultations, subscriptions, clinical programs, software, devices, pharmacy services, or a combination of those offerings. The strongest business models are increasingly judged by recurring revenue, patient engagement, integrated care delivery, and measurable outcomes rather than raw visit volume.
The sector includes several distinct layers. Direct-to-consumer platforms such as subscription-based health services target convenience and retention, while enterprise providers sell virtual-care infrastructure to employers, health plans, hospitals, and health systems. Chronic-care management, behavioral health, weight management, remote monitoring, and hybrid workflows add further depth. Teladoc’s integrated platform, LifeMD’s telehealth and pharmacy services, Hims & Hers’ consumer model, and Omada Health’s employer- and payer-oriented programs illustrate how the category is becoming embedded in the broader healthcare operating system.
This countdown ranks seven telehealth-related stocks by investment quality, with the ranking balancing business positioning, financial performance, growth, valuation, profitability, earnings execution, and analyst sentiment. The list runs from #7 to #1, so the strongest overall selection appears at the end. Some companies offer direct virtual care, while others provide the technology, physician-enablement tools, or disease-management programs that can make telehealth more scalable and economically useful.
Our screen focused on US-listed companies connected to telehealth, virtual care, health-information services, or digitally enabled healthcare, with a universe constraint of market capitalization above $500 million at the time of screening. We ranked the eligible names using our composite quality grade alongside revenue and earnings trends, margins, balance-sheet considerations, valuation measures, earnings history, and analyst consensus. This is a countdown rather than a flat watchlist: the best pick is intentionally reserved for #1, which appears at the end.
What they do. The company provides telehealth solutions for acutely ill patients in neurointensive care, cardiac intensive care, and intensive care units. Its iDoc offerings address conditions such as stroke, spinal cord injury, and brain trauma, while its software building blocks cover patient engagement, clinician staffing, remote physical exams, remote monitoring, data connectors, workflow templates, and AI-supported telesitter and telenursing solutions. VSee sells through affiliated hospitals, third-party resellers, and sales executives, giving it a specialized clinical focus rather than a broad consumer footprint.
Why it fits. VSee targets one of telehealth’s most consequential use cases: extending specialist coordination and monitoring into high-acuity hospital settings. Its remote physical-exam, remote-monitoring, telesitter, and telenursing capabilities align with the industry’s shift toward hybrid workflows that connect virtual clinicians with in-person care teams. That focus could make the platform clinically relevant, but the financial profile currently provides limited evidence of scale.
Numbers that matter. Revenue was $14.46 million, with year-over-year revenue declining 4.9%. Gross margin was 46.3%, but operating margin was -94.12% and net margin was -92.37%; EBITDA was negative $8.14 million. The company also reported negative ROE of -9.457 and negative ROA of -0.349, while trailing EPS was -$0.54 and next-year EPS is estimated at -$0.36. Those figures explain the C- composite grade and place VSee well below the more established platforms in this ranking.
Recent momentum. The latest reported EPS was -$0.0543 on June 3, 2026, following EPS of -$0.3127 on February 25. The earnings history shows a 1/2 beat rate among quarters with available estimates; the November 2025 result beat by 75.0%, but the August 2025 result missed by 300.0%. Analyst coverage shows one Buy and no listed Hold or Sell count, with an average target of $5, but the small scale, declining revenue, and deep operating loss keep VSee at the bottom of this quality-ranked list.
What they do. Privia is a physician-enablement company that works with physician practices, health plans, and health systems. It combines workflow and population-health technology with management services, a single-TIN medical group, an accountable care organization, and a purchaser and payer network. That model supports providers with administrative work, clinical integration, negotiating power, patient coordination, and value-based-care incentives, making Privia more of a healthcare infrastructure and enablement business than a pure telehealth visit provider.
Why it fits. Privia fits the broader telehealth theme through the digital workflows and population-health tools that help physicians coordinate care across settings. Its accountable-care and network capabilities connect virtual access with value-based care, where reducing inappropriate utilization and improving patient quality metrics can matter more than maximizing individual visits. The company therefore offers exposure to the hybrid, payer-aligned side of telehealth, although its business is broader than virtual care alone.
Numbers that matter. Privia generated $2.25 billion of revenue, up 25.8% year over year, and EBITDA was $47.73 million. Profitability remains thin: gross margin was 10.0%, operating margin was 1.23%, and net margin was 0.97%, with ROE of 0.0362 and ROA of 0.0175. Trailing P/E was 139.2353, versus a forward P/E of 26.0417, while EPS was $0.17 and next-year EPS is estimated at $1.0975. The sharp difference between trailing and forward valuation makes execution on the earnings outlook important.
Recent momentum. Privia’s earnings beat rate was 4/7. The May 7, 2026 report missed estimates by 24.0%, with EPS of $0.19 versus $0.25, after a February beat of 75.0% with EPS of $0.07 versus $0.04. Analysts remain constructive overall, with five Buys and two Holds and an average target of $31.8947. The next report was scheduled for August 6 with an EPS estimate of $0.08, giving investors a near-term test of whether strong revenue growth can translate into more durable profitability.
What they do. American Well provides enterprise software and digitally enabled hybrid care in the United States and internationally. Its Amwell Platform supports care delivery across settings, while Amwell Carepoint adds connected carts and digital access points, and Amwell Converge integrates digital care with in-person and automated workflows. The company also offers behavioral health, specialty programs, medical-group network services, implementation, systems integration, and patient and provider engagement services to providers, payers, government customers, and higher education.
Why it fits. American Well is closely aligned with the enterprise layer of telehealth. Rather than relying only on consumer visits, it sells the platform, devices, specialty programs, and professional services that can help institutions build virtual access into existing clinical operations. Its hybrid-care positioning is particularly relevant as hospitals and payers seek workflows that blend remote clinicians, in-person staff, behavioral health, and specialty care.
Numbers that matter. Revenue was $237.38 million, down 17.9% year over year, and EBITDA was negative $46.32 million. Gross margin was a relatively strong 53.8%, but operating margin was -23.59% and net margin was -37.02%; ROE was -0.3184 and ROA was -0.1343. EPS was -$5.43 on a trailing basis, with next-year EPS estimated at -$1.68. The platform opportunity is meaningful, but contracting revenue and continued losses limit the stock’s investment-quality score.
Recent momentum. American Well has beaten estimates in 6 of the last 7 reported quarters. In May 2026, EPS was -$0.67 versus an estimate of -$0.77, a 13.0% beat; the February result beat by 29.6%. However, the latest consensus profile consists of eight Holds, with a consensus score of 3.2222/5 and an average target of $8.9. The next earnings report was scheduled for August 4 with an EPS estimate of -$0.60, so improving loss control remains central to the thesis.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do. LifeMD is a direct-to-patient telehealth company that combines virtual medical care with pharmacy services. Its Rex MD platform addresses men's health conditions including erectile dysfunction, hair loss, insomnia, weight loss, and performance anxiety, while ShapiroMD focuses on hair-loss treatment and related products. LifeMD PC provides primary, urgent, and chronic care, and the broader platform includes consultations, prescriptions, diagnostics, wellness coaching, in-home tools, GLP-1 weight management, and health-monitoring devices.
Why it fits. LifeMD represents the direct-to-consumer and integrated-pharmacy side of telehealth. The combination of consultation, prescription fulfillment, specialty platforms, chronic-care access, and at-home monitoring can support a more complete customer relationship than a one-off virtual visit. Its focus on men's health, hair loss, primary care, weight management, and related services also gives the company several potential engagement pathways within a subscription-oriented model.
Numbers that matter. LifeMD posted revenue growth of -1.4%, with revenue of $193.33 million and EBITDA of negative $14.30 million. Gross margin was 86.8%, while operating margin was -17.8%; net margin was 2.93%, creating a mixed profitability picture. Trailing EPS was -$0.44, but next-year EPS is estimated at $0.515, and forward P/E was 12.8535. The high gross margin and projected EPS improvement are positives, but the revenue decline, negative operating margin, and D+ quality grade point to substantial execution risk.
Recent momentum. The earnings beat rate was only 2/7. The May 2026 report missed by 29.9%, with EPS of -$0.1516 versus -$0.1167, and the March report missed by 33.3%, with EPS of $0.06 versus $0.09. Analysts nevertheless show one Buy and one Hold, with a consensus score of 4.625/5 and an average target of $9.875. The next report was scheduled for August 5 with an EPS estimate of -$0.20, making near-term profitability evidence especially important.
What they do. Teladoc provides virtual healthcare worldwide through its Teladoc Health Integrated Care and BetterHelp segments. Integrated Care includes general, expert, specialty, chronic-condition, and mental-health services, along with enterprise telehealth technology for hospitals and health systems. BetterHelp provides online counseling and therapy through websites, applications, phone, and text interactions. The company serves employers, health plans, hospitals, insurers, financial-services companies, and individual members, giving it one of the broadest distribution models in the category.
Why it fits. Teladoc remains a foundational telehealth name because it spans direct virtual care, enterprise technology, chronic-condition management, and behavioral health. Its integrated-care platform is moving beyond basic video visits, with access fees, visit fees, and virtual-care device revenue represented in its broader model. That combination provides exposure to the healthcare operating-system thesis, although the company must stabilize revenue and convert its scale into consistent profits.
Numbers that matter. Teladoc generated $2.49 billion of revenue, but year-over-year revenue declined 4.0%. Gross margin was 69.0%, EBITDA was $64.56 million, and operating and net margins were -5.68% and -7.13%, respectively. ROE was -0.1299 and ROA was -0.0322, while trailing EPS was -$0.99 and next-year EPS is estimated at -$0.615. The forward P/E of 303.0303 is difficult to justify without a clearer return to earnings growth, despite the company’s scale and a DCF component rated favorably in the composite metrics.
Recent momentum. Teladoc has beaten EPS estimates in all 8 of the last 8 reported quarters. The July 29, 2026 report produced EPS of -$0.21 versus an estimate of -$0.24, a 12.5% beat, following a 28.2% beat in April. Analyst coverage is more cautious than the earnings record: two analysts list Buy and 19 list Hold, producing a 3.3333/5 consensus and an average target of $7.7632. The next report was scheduled for October 28.
Pick #2Premium members only
Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
The ranking uses a quality-first framework built from primary-source financial data and our composite metrics. We considered each company’s telehealth exposure, business model, market position, market capitalization, revenue growth, EPS trend, gross and operating margins, return measures, EBITDA, valuation, earnings surprises, and analyst consensus. Companies were ordered from #7 to #1, with the highest overall investment-quality assessment assigned the final position. The article is refreshed monthly, so valuation measures, market capitalization, earnings histories, and analyst expectations may change between editions. The ranking is research context, not a guarantee of future operating or market performance.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
